OUR PRODUCTS
Innovative solutions to deliver radically better cancer care
Each product targets a critical challenge in cancer care - reducing treatment toxicity, expanding capacity, or supporting patients during treatment. Our ambition is to improve outcomes for payers and their members. And we’re just getting started.
Clinically validated
Workflow-ready
Outcomes-focused
OUR PRODUCTS
Innovative solutions to deliver radically better cancer care
Each product targets a critical challenge in cancer care - reducing treatment toxicity, expanding capacity, or supporting patients during treatment. Our ambition is to improve outcomes for payers and their members. And we’re just getting started.
Clinically validated
Workflow-ready
Outcomes-focused
OUR PRODUCTS
Innovative solutions to deliver radically better cancer care
Each product targets a critical challenge in cancer care - reducing treatment toxicity, expanding capacity, or supporting patients during treatment. Our ambition is to improve outcomes for payers and their members. And we’re just getting started.
Clinically validated
Workflow-ready
Outcomes-focused
LOTUS
Lotus
Bringing cancer treatment closer to home.
Lotus safely enables low-risk cancer treatment infusions at home, reducing clinic visits and freeing up oncology capacity. It seamlessly integrates into existing protocols and supports remote monitoring for uninterrupted care.
Fits into existing workflows
Clinically Validated
Improves Treatment Adherence
Enhances Quality of Life
![](data:image/svg+xml,<svg display="block" role="presentation" viewBox="0 0 35 40" xmlns="http://www.w3.org/2000/svg"><path d="M 10.898 30.794 C 7.314 31.947 3.428 31.723 0 30.166 C 0.37 26.374 2.156 22.862 5.002 20.329 L 5.064 20.381 C 5.745 20.949 6.473 21.458 7.24 21.902 C 8.47 22.609 9.79 23.146 11.165 23.497 C 10.781 24.872 10.586 26.281 10.586 27.692 C 10.587 28.713 10.687 29.731 10.885 30.732 Z M 23.291 31.103 L 23.351 31.125 C 22.518 34.707 20.408 37.862 17.416 40 C 14.425 37.861 12.315 34.706 11.481 31.125 L 11.541 31.103 C 12.421 30.786 13.272 30.391 14.073 29.929 C 15.3 29.218 16.425 28.343 17.416 27.329 C 19.066 29.014 21.075 30.305 23.294 31.103 Z M 29.83 20.331 L 29.828 20.332 C 29.828 20.332 29.827 20.331 29.827 20.331 Z M 29.828 20.332 C 32.675 22.864 34.462 26.377 34.832 30.168 C 31.464 31.696 27.576 31.973 23.934 30.796 L 23.946 30.735 C 24.144 29.725 24.246 28.705 24.246 27.695 C 24.246 26.283 24.05 24.874 23.667 23.499 C 25.042 23.148 26.362 22.612 27.591 21.904 C 28.358 21.46 29.086 20.951 29.767 20.383 Z M 23.939 9.206 C 27.523 8.052 31.409 8.276 34.837 9.834 C 34.466 13.626 32.679 17.139 29.832 19.671 L 29.77 19.619 C 29.078 19.043 28.346 18.531 27.594 18.098 C 26.37 17.393 25.052 16.86 23.669 16.503 C 24.053 15.128 24.249 13.719 24.249 12.308 C 24.247 11.287 24.147 10.269 23.949 9.268 L 23.937 9.206 Z M 11.544 8.897 L 11.484 8.875 C 12.317 5.293 14.427 2.138 17.419 0 C 20.41 2.139 22.52 5.294 23.354 8.875 L 23.294 8.897 C 22.417 9.213 21.569 9.606 20.762 10.072 C 19.535 10.782 18.41 11.656 17.419 12.67 C 15.769 10.985 13.76 9.695 11.541 8.897 Z M 5.065 19.619 L 5.067 19.619 L 5.005 19.671 C 2.157 17.14 0.37 13.626 0 9.834 C 3.428 8.277 7.314 8.053 10.898 9.206 L 10.886 9.268 C 10.687 10.277 10.586 11.298 10.586 12.307 C 10.588 13.725 10.782 15.137 11.165 16.503 C 9.79 16.853 8.47 17.39 7.24 18.098 C 6.474 18.543 5.746 19.052 5.065 19.619 Z" fill="rgb(198, 188, 244)" height="40.00000047302247px" id="FhfknWWzM" width="34.83700062561036px"/></svg>)
Timeline
Our journey doesn’t stop at the clinic. Each stage brings Lotus closer to enabling safe, at-home cancer care for more patients.
Now
Piloting with trained nurses delivering at-home infusions in select U.S. clinics.
Next
Enabling patient led home infusions with the Lotus infusion set.
Future
Expanding the cohort of patients who are eligible for home treatment using novel monitoring technologies.
LOTUS
Lotus
Bringing cancer treatment closer to home.
Lotus safely enables low-risk cancer treatment infusions at home, reducing clinic visits and freeing up oncology capacity. It seamlessly integrates into existing protocols and supports remote monitoring for uninterrupted care.
Fits into existing workflows
Clinically Validated
Improves Treatment Adherence
Enhances Quality of Life
Timeline
Our journey doesn’t stop at the clinic. Each stage brings Lotus closer to enabling safe, at-home cancer care for more patients.
Now
Piloting with trained nurses delivering at-home infusions in select U.S. clinics.
Next
Enabling patient led home infusions with the Lotus infusion set.
Future
Expanding the cohort of patients who are eligible for home treatment using novel monitoring technologies.
LOTUS
Lotus
Bringing cancer treatment closer to home.
Lotus safely enables low-risk cancer treatment infusions at home, reducing clinic visits and freeing up oncology capacity. It seamlessly integrates into existing protocols and supports remote monitoring for uninterrupted care.
Fits into existing workflows
Clinically Validated
Improves Treatment Adherence
Enhances Quality of Life
Timeline
Our journey doesn’t stop at the clinic. Each stage brings Lotus closer to enabling safe, at-home cancer care for more patients.
Now
Piloting with trained nurses delivering at-home infusions in select U.S. clinics.
Next
Enabling patient led home infusions with the Lotus infusion set.
Future
Expanding the cohort of patients who are eligible for home treatment using novel monitoring technologies.
LOTUS
Lotus
Bringing cancer treatment closer to home.
Lotus safely enables low-risk cancer treatment infusions at home, reducing clinic visits and freeing up oncology capacity. It seamlessly integrates into existing protocols and supports remote monitoring for uninterrupted care.
Fits into existing workflows
Clinically Validated
Improves Treatment Adherence
Enhances Quality of Life
Timeline
Our journey doesn’t stop at the clinic. Each stage brings Lotus closer to enabling safe, at-home cancer care for more patients.
Now
Piloting with trained nurses delivering at-home infusions in select U.S. clinics.
Next
Enabling patient led home infusions with the Lotus infusion set.
Future
Expanding the cohort of patients who are eligible for home treatment using novel monitoring technologies.
LILAC
Lilac
Simplify side effect management
Reduces the risk of drug-induced peripheral neuropathy (DIPN) - a leading cause of dose reductions and treatment dropouts.
Helps maintain treatment intensity, improve outcomes, and ease the burden of side-effect management.
Fits into existing workflows
Support dose adherence
Reduce risk of DIPN
Timeline
Our journey doesn’t stop at the clinic.
Now
Clinical trials are underway in multiple sites across the U.S.
Next
Proof of concept data showing efficacy in taxane and platinum patients.
Future
Aim to be FDA approved in 2026
LILAC
Lilac
Simplify side effect management
Reduces the risk of drug-induced peripheral neuropathy (DIPN) - a leading cause of dose reductions and treatment dropouts.
Helps maintain treatment intensity, improve outcomes, and ease the burden of side-effect management.
Fits into existing workflows
Support dose adherence
Reduce risk of DIPN
Timeline
Our journey doesn’t stop at the clinic.
Now
Clinical trials are underway in multiple sites across the U.S.
Next
Proof of concept data showing efficacy in taxane and platinum patients.
Future
Aim to be FDA approved in 2026
LILAC
Lilac
Simplify side effect management
Reduces the risk of drug-induced peripheral neuropathy (DIPN) - a leading cause of dose reductions and treatment dropouts.
Helps maintain treatment intensity, improve outcomes, and ease the burden of side-effect management.
Fits into existing workflows
Support dose adherence
Reduce risk of DIPN
Timeline
Our journey doesn’t stop at the clinic.
Now
Clinical trials are underway in multiple sites across the U.S.
Next
Proof of concept data showing efficacy in taxane and platinum patients.
Future
Aim to be FDA approved in 2026
LOTUS
Lilac
Simplify side effect management
Reduces the risk of drug-induced peripheral neuropathy (DIPN) - a leading cause of dose reductions and treatment dropouts.
Helps maintain treatment intensity, improve outcomes, and ease the burden of side-effect management.
Fits into existing workflows
Support dose adherence
Reduce risk of DIPN
Timeline
Our journey doesn’t stop at the clinic.
Now
Clinical trials are underway in multiple sites across the U.S.
Next
Proof of concept data showing efficacy in taxane and platinum patients.
Future
Aim to be FDA approved in 2026
LILY
Lily
Supporting identity through treatment.
Helps reduce cancer treatment related hair loss - supporting patients through one of treatment’s most visible and emotional side effects.
Preserves a sense of identity while enhancing the overall care experience.
To reduce hair loss
Improves emotional wellbeing
Supports clinic engagement
Designed with empathy
Timeline
Our journey doesn’t stop at the clinic.
Now
Proof of concept in several chemotherapy regimens
Next
Release of results from PREVAIL multicentral clinical study
Future
Commercial roll-out and expansion into ADCs
LILY
Lily
Supporting identity through treatment.
Helps reduce cancer treatment related hair loss - supporting patients through one of treatment’s most visible and emotional side effects.
Preserves a sense of identity while enhancing the overall care experience.
To reduce hair loss
Improves emotional wellbeing
Supports clinic engagement
Designed with empathy
Timeline
Our journey doesn’t stop at the clinic.
Now
Proof of concept in several chemotherapy regimens
Next
Release of results from PREVAIL multicentral clinical study
Future
Commercial roll-out and expansion into ADCs
LILY
Lily
Supporting identity through treatment.
Helps reduce cancer treatment related hair loss - supporting patients through one of treatment’s most visible and emotional side effects.
Preserves a sense of identity while enhancing the overall care experience.
To reduce hair loss
Improves emotional wellbeing
Supports clinic engagement
Designed with empathy
Timeline
Our journey doesn’t stop at the clinic.
Now
Proof of concept in several chemotherapy regimens
Next
Release of results from PREVAIL multicentral clinical study
Future
Commercial roll-out and expansion into ADCs
LOTUS
Lily
Supporting identity through treatment.
Helps reduce cancer treatment related hair loss - supporting patients through one of treatment’s most visible and emotional side effects.
Preserves a sense of identity while enhancing the overall care experience.
To reduce hair loss
Improves emotional wellbeing
Supports clinic engagement
Designed with empathy
Timeline
Our journey doesn’t stop at the clinic.
Now
Proof of concept in several chemotherapy regimens
Next
Release of results from PREVAIL multicentral clinical study
Future
Commercial roll-out and expansion into ADCs
And we’re just getting started.
We’re moving fast to solve more of what’s missing in cancer care—from early-stage side effects to at-home monitoring and recovery support. It takes a team to change how cancer care works. If you're driven to build smarter, more human solutions,
And we’re just getting started.
We’re moving fast to solve more of what’s missing in cancer care—from early-stage side effects to at-home monitoring and recovery support. It takes a team to change how cancer care works. If you're driven to build smarter, more human solutions,
And we’re just getting started.
We’re moving fast to solve more of what’s missing in cancer care—from early-stage side effects to at-home monitoring and recovery support. It takes a team to change how cancer care works. If you're driven to build smarter, more human solutions,
Let’s improve cancer care, together.
If you're interested in piloting, collaborating, or simply learning more about how our technologies can fit your practice, we’d love to hear from you.
Let’s improve cancer care, together.
If you're interested in piloting, collaborating, or simply learning more about how our technologies can fit your practice, we’d love to hear from you.
Let’s improve cancer care, together.
If you're interested in piloting, collaborating, or simply learning more about how our technologies can fit your practice, we’d love to hear from you.
We build technologies that help oncologists make cancer care better for patients.
People want to live, not just survive. We are building technology that aims to enable patients to improve their own experience of healthcare.
Information on this website pertains to pre-clinical or clinical-stage medical devices in development that have not been approved by the Food and Drug Administration.
FUNDED BY
On Trial At
Featured In
We build technologies that help oncologists make cancer care better for patients.
People want to live, not just survive. We are building technology that aims to enable patients to improve their own experience of healthcare.
Information on this website pertains to pre-clinical or clinical-stage medical devices in development that have not been approved by the Food and Drug Administration.
FUNDED BY
On Trial At
Featured In
We build technologies that help oncologists make cancer care better for patients.
People want to live, not just survive. We are building technology that aims to enable patients to improve their own experience of healthcare.
Information on this website pertains to pre-clinical or clinical-stage medical devices in development that have not been approved by the Food and Drug Administration.
FUNDED BY
On Trial At
Featured In